Munich, Monday 15 January 2018 06.35 CET
A randomized controlled trial (RCT) has provided powerful evidence that adding our digital software significantly improves inpatient treatment efficacy. This clinical study was conducted by leading, independent researchers at the University Medical Center Mainz, Germany. The results have been published in the prestigious medical journal, Psychotherapy and Psychosomatics.
All 229 patients enrolled in the study had been diagnosed with a depressive disorder. They were hospitalized for an average of 40 days and received regular inpatient psychotherapy. Patients were randomized into either an intervention or an active control group.
The intervention group was given access to deprexis®. However, the control group received regular online information on depression. This is the psychological equivalent of a drug placebo, which is a notable methodological strength of this trial.
After three months, depressive symptoms were lower among patients in the intervention group when compared to the control group. Also, the extent of depressive symptom reduction was twice as large in the group treated with deprexis® (d=1.12) than in the control group (d=0.56). Significant intervention effects were also found for anxiety symptoms, quality of life, and self-esteem.
This landmark study demonstrates that our innovative software can reliably double the effectiveness of inpatient treatment. This could potentially advance the nature of treatment delivery.
The article is available at https://doi.org/10.1159/000481177